GDTC CytoMed Therapeutics Ltd: Forvard narx/daromad multiplikatori
CytoMed Therapeutics (GDTC) ichki xatarlarni minimallashtirish uchun tashqi pudratchilar orqali hujayra mahsulotlari sinovlarini optimallashtirmoqda. Bashorat qilingan P/S baholash ko'rsatkichi joriy bozor dinamikasini aks ettiradi, bunda 39.90 qiymati metrika darajasini belgilaydi. Fundamental ko'rsatkichlar onkologiya uchun NK-terapiya ishlanmalariga va Singapurda joylashgan boshqaruv jamoasining kuchli ilmiy tajribasiga tayanadi, ular erta bosqichdagi klinik sinovlar uchun resurslarni samarali taqsimlaydi.
GDTC (w2.cytomed.sg): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar
- aksiya narxi va konsensus maqsadli narx:
- kompaniya aksiyalari kapitallashuvi ma'lumotlari:
- biznesning balans baholash tafsilotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Umumiy qarzning kapitalga nisbati CytoMed Therapeutics|GDTC - Uzoq muddatli majburiyatlarning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati CytoMed Therapeutics Limited|GDTC - Kompaniyaning jamlangan qarzi|Qarzning balans qiymatiga nisbati CytoMed Therapeutics Limited|GDTC - Kompaniyaning uzoq muddatli kredit va qarzlari|Kompaniyaning qisqa muddatli majburiyatlari CytoMed Therapeutics|Tezkor likvidlik koeffitsiyenti w2.cytomed.sg
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
GDTC - Yakuniy foyda|Prognoz qilingan kelajakdagi foyda CytoMed Therapeutics|GDTC - Kapitalizatsiyaning foydaga nisbati|Kelajakdagi narxning foydaga nisbati CytoMed Therapeutics Limited|GDTC - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|EV/EBITDA multiplikatori CytoMed Therapeutics Limited|GDTC - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bir aksiya uchun foyda CytoMed Therapeutics|GDTC - So'nggi 12 oy davomida bitta aksiya uchun foyda|Choraklik EPS foyda o'sishi w2.cytomed.sg|GDTC - Joriy yilda bir aksiya uchun foydaning o'sish sur'ati|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi CytoMed Therapeutics
- tushum va sotuvlar tafsilotlari:
Kompaniyaning fundamental baholanishi:CytoMed (GDTC)
Forward P/S biznesning joriy bozor qiymatini prognoz qilingan kelajakdagi savdo aylanmasi bilan solishtiradi, bu esa investorga kutilayotgan daromad o'sish sur'atlari uchun to'langan premium miqdorini baholash imkonini beradi. Hozirda o'z bio-platformasining xavfsizlikni tasdiqlash bosqichida bo'lgan CytoMed Therapeutics (GDTC) uchun kutilayotgan narx-savdo nisbati kelajakdagi farmatsevtika ittifoqlari potensialiga bo'lgan bozor ishonchining ko'rsatkichi bo'lib xizmat qiladi va rivojlanish strategiyasining fundamental barqarorligini tasdiqlaydi.
Muhim raqobatchilar
BeiGene - Forvard narx/daromad multiplikatori|Halozyme Therapeutics, Inc. (HALO) - Bozor kapitallashuvining kelajakdagi daromadga nisbati|RVMD: Forvard narx/daromad multiplikatori|Ascentage Pharma Corp - Narxning kutilayotgan daromadga nisbati|CG Oncology, Inc. (CGON) - Narxning prognoz qilingan daromadga nisbati|Bozor kapitallashuvining kelajakdagi daromadga nisbati urogen.com (URGN)|Narxning prognoz qilingan daromadga nisbati Bicara Therapeutics|Forvard narx/daromad multiplikatori Personalis Inc (PSNL)|Forvard P/S multiplikatori ERAS|DCTH - Bozor kapitallashuvining kelajakdagi daromadga nisbati|Forvard P/S multiplikatori YMAB (Y-mAbs Therapeutics)|AURA: Kapitalizatsiyaning prognoz qilingan daromadga nisbati|CADL: Forvard narx/daromad multiplikatori|Sotuvga nisbatan forvard narx ARAY (Accuray Inc)|SLS (sellaslifesciences.com) - Forvard narx/daromad multiplikatori|ACTU: Narxning kutilayotgan daromadga nisbati|CTOR (Citius Oncology, Inc.) - Forvard P/S multiplikatori|HURA: Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori TARA|FATE - Bozor kapitallashuvining kelajakdagi daromadga nisbati|Narxning prognoz qilingan daromadga nisbati Aadi Bioscience WHWK|Sotuvga nisbatan forvard narx TCRX|Champions Oncology Corp - Forvard P/S multiplikatori|XBIT - Forvard P/S multiplikatori|cel-sci.com (CVM) - Narxning prognoz qilingan daromadga nisbati|Kelajakdagi narxning daromadga nisbati OSTX (OS Therapies Inc.)|RADX (Radiopharm Theranostics Limited) - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Artiva ARTV|Forvard narx/daromad multiplikatori ANL (Adlai Nortye Ltd.)|Forvard P/S multiplikatori verupharma.com (VERU)|Tempest Therapeutics, Inc. - Forvard narx/daromad multiplikatori|Narxning kutilayotgan daromadga nisbati XLO (Xilio Therapeutics Inc)|Enochian BioSciences - Forvard P/S multiplikatori|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Mural Oncology plc MURA|KAPA: Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori OnKure Therapeutics|Narxning prognoz qilingan daromadga nisbati Curis Inc.|Apollomics Corp (APLM) - Kapitalizatsiyaning kutilayotgan sotuvga nisbati|Forvard P/S multiplikatori THAR|advanbiomed.com (ADVB) - Prognoz narxning daromadga nisbati|Forvard P/S multiplikatori GNPX (Genprex, Inc.)|CLDI: Kapitalizatsiyaning prognoz qilingan daromadga nisbati|SBFM: Forvard narx/daromad multiplikatori|Xenetic Biosciences - Narxning kutilayotgan daromadga nisbati|SLRX: Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori Kitov Pharma|AONC (American Oncology Network Inc) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori beigene.com (BGNE)|Forvard P/S multiplikatori CKPT|Forvard P/S multiplikatori elevationoncology.com (ELEV)|Narxning prognoz qilingan daromadga nisbati iCAD ICAD|IKNA: Kapitalizatsiyaning prognoz qilingan daromadga nisbati|Notable Labs, Ltd. - Forvard P/S multiplikatori|Viracta Therapeutics (VIRX) - Forvard narx/daromad multiplikatori|MOR: Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati NAYA Biosciences Inc (NAYA)|Narxning prognoz qilingan daromadga nisbati Ascentage Pharma Group Ltd
